logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11096910 B1

PDFFull Text
Date of Patent:
Aug. 24, 2021

Filed:

Jul. 22, 2016

Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease

Applicants:

Omeicos Therapeutics Gmbh, Berlin, DE;

Board of Regents, the University of Texas System, Austin, TX (US);

Max Delbruck-centrum Fur Molekulare Medizin, Berlin, DE;

Inventors:

Robert Fischer, Berlin, DE;

Anne Konkel, Berlin, DE;

Tim Wesser, Berlin, DE;

Philipp Westphal, Berlin, DE;

Wolf-Hagen Schunk, Berlin, DE;

Christina Westphal, Berlin, DE;

John Russell Falck, Dallas, TX (US);

Assignees:

Max Delbruck-Centrum Fur Molekulare Medizin, Berlin, DE;

The Board of Regents of the University of Texas System, Austin, TX (US);

Omeicos Therapeutics GmbH, Berlin, DE;

Attorney:

McDonnell Boehnen Hulbert & Berghoff LLP

Primary Examiner:

Theodore R Howell

Int. Cl.
CPC ...
A61P 9/00 (2006.01); A61K 31/08 (2006.01); A61K 31/202 (2006.01); A61K 31/18 (2006.01); C07C 233/56 (2006.01); C07C 275/20 (2006.01); C07C 311/17 (2006.01); C07D 257/04 (2006.01); C07C 311/51 (2006.01); C07D 307/60 (2006.01); C07D 295/192 (2006.01); C07D 309/14 (2006.01); C07D 249/12 (2006.01); C07D 263/48 (2006.01); A61K 31/557 (2006.01); A61P 9/10 (2006.01); A61P 9/06 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 31/17 (2006.01); A61K 31/4196 (2006.01); A61K 31/5375 (2006.01);
U.S. Cl.
CPC ...
A61K 31/18 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 9/12 (2013.01); A61K 31/202 (2013.01); A61K 31/557 (2013.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 9/10 (2018.01); C07C 233/56 (2013.01); C07C 275/20 (2013.01); C07C 311/17 (2013.01); C07C 311/51 (2013.01); C07D 249/12 (2013.01); C07D 257/04 (2013.01); C07D 263/48 (2013.01); C07D 295/192 (2013.01); C07D 307/60 (2013.01); C07D 309/14 (2013.01); A61K 31/17 (2013.01); A61K 31/4196 (2013.01); A61K 31/5375 (2013.01);
Abstract

The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of cardiovascular diseases.

Find Patent Forward Citations

Loading…